Cargando…

Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis

BACKGROUND: Patients with multiple sclerosis (pwMS) are often treated with disease modifying therapies (DMT) with immunomodulatory effects. This is of particular concern following the development of several vaccines to combat coronavirus disease 19 (COVD-19), a potentially fatal illness caused by SA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gyang, Tirisham V., Evans, John P., Miller, Joseph S., Alcorn, Kariss, Peng, Juan, Bell, Erica H., Zeng, Cong, Gumina, Richard, Liu, Shan-Lu, Segal, Benjamin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941285/ https://www.ncbi.nlm.nih.gov/pubmed/35342640 http://dx.doi.org/10.1177/20552173221087357

Ejemplares similares

Anti-JCV antibody index does not change during ocrelizumab-treatment
por: Rempe, Torge, et al.
Publicado: (2020)

Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection
por: Evans, John P., et al.
Publicado: (2022)

Loss of Neutralizing Antibody Response to mRNA Vaccination against SARS-CoV-2 Variants: Differing Kinetics and Strong Boosting by Breakthrough Infection
por: Evans, John P., et al.
Publicado: (2021)

Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant
por: Qu, Panke, et al.
Publicado: (2022)

Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant
por: Qu, Panke, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H
por: Zeng, Cong, et al.
Publicado: (2021)

Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants
por: Evans, John P., et al.
Publicado: (2022)

Neutralization and Stability of SARS-CoV-2 Omicron Variant
por: Zeng, Cong, et al.
Publicado: (2021)

Erratum for Zeng et al., “Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H”
por: Zeng, Cong, et al.
Publicado: (2021)

Impaired Neutralizing Antibody Response to COVID-19 mRNA Vaccines in Cancer Patients
por: Zeng, Cong, et al.
Publicado: (2021)

Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients
por: Zeng, Cong, et al.
Publicado: (2021)

Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants
por: Qu, Panke, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
por: Evans, John P., et al.
Publicado: (2022)

Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors
por: Weidenbacher, Payton A.-B., et al.
Publicado: (2022)

Neutralizing antibodies targeting the SARS‐CoV‐2 receptor binding domain isolated from a naïve human antibody library
por: Bell, Benjamin N., et al.
Publicado: (2021)

Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors
por: Zeng, Cong, et al.
Publicado: (2020)

Neutralizing antibody titres in SARS-CoV-2 infections
por: Lau, Eric H. Y., et al.
Publicado: (2021)

Antibody-mediated neutralization of SARS-CoV-2
por: Gruell, Henning, et al.
Publicado: (2022)

Neutralizing antibodies for SARS-CoV-2 infection
por: Berenguer, Juan
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
por: Qu, Panke, et al.
Publicado: (2022)

SARS-CoV-2 neutralizing antibody development strategies
por: BALCIOĞLU, Bertan Koray, et al.
Publicado: (2020)

Human antibodies can neutralize SARS-CoV-2
por: Catalan-Dibene, Jovani
Publicado: (2020)

Neutralizing and enhancing antibodies against SARS-CoV-2
por: Liu, Yafei, et al.
Publicado: (2022)

Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
por: Vanshylla, Kanika, et al.
Publicado: (2022)

Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody
por: Liu, Kuan-Ting, et al.
Publicado: (2022)

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants
por: Cho, Hyeseon, et al.
Publicado: (2021)

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
por: Creeke, Paul I., et al.
Publicado: (2013)

Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection
por: Zhang, Ali, et al.
Publicado: (2022)

Track-etched membrane microplate and smartphone immunosensing for SARS-CoV-2 neutralizing antibody
por: Wang, Cong, et al.
Publicado: (2021)

Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques
por: Ishigaki, Hirohito, et al.
Publicado: (2021)

The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin
por: Miller, Aaron L., et al.
Publicado: (2022)

Antibody-like proteins that capture and neutralize SARS-CoV-2
por: Kondo, T., et al.
Publicado: (2020)

Perspectives on the development of neutralizing antibodies against SARS-CoV-2
por: Ho, Mitchell
Publicado: (2020)

Neutralizing antibodies targeting SARS-CoV-2 spike protein
por: Xiaojie, Shi, et al.
Publicado: (2021)

Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies
por: Xue, Jun-biao, et al.
Publicado: (2021)

Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers
por: Rujas, Edurne, et al.
Publicado: (2021)

Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy
por: Zhou, Dongyan, et al.
Publicado: (2021)

SARS-CoV-2 re-infection, vaccination and neutralizing antibodies
por: Bongiovanni, Marco, et al.
Publicado: (2022)

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
por: Anichini, Gabriele, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fvbsf5tuh16q1bm6bnsvd05rjo